Wilbur D S, Pathare P M, Hamlin D K, Stayton P S, To R, Klumb L A, Buhler K R, Vessella R L
Department of Radiation Oncology, University of Washington, Seattle 98195, USA.
Biomol Eng. 1999 Dec 31;16(1-4):113-8. doi: 10.1016/s1050-3862(99)00044-3.
The high affinity of biotin for streptavidin has made this pair of molecules very useful for in vivo applications. To optimize reagents for one potential in vivo application, antibody-based pretargeting of cancer, we have prepared a number of new biotin and streptavidin derivatives. The derivatives developed include new radiolabeled biotin reagents, new protein biotinylation reagents, and new biotin multimers for cross-linking and/or polymerization of streptavidin. We have also modified streptavidin by site-directed mutation and chemical modification to improve its in vivo characteristics, and have developed new reagents for cross-linking antibody fragments with streptavidin. A brief overview of these new reagents is provided.
生物素与链霉亲和素的高亲和力使得这对分子在体内应用中非常有用。为了优化一种潜在的体内应用（基于抗体的癌症预靶向）的试剂，我们制备了许多新的生物素和链霉亲和素衍生物。开发的衍生物包括新的放射性标记生物素试剂、新的蛋白质生物素化试剂以及用于链霉亲和素交联和/或聚合的新生物素多聚体。我们还通过定点突变和化学修饰对链霉亲和素进行了改造，以改善其体内特性，并开发了用于将抗体片段与链霉亲和素交联的新试剂。本文对这些新试剂进行了简要概述。
